SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...
Please provide your email address to receive an email when new articles are posted on . ADP101 includes 15 substances from the nine most common food allergens. 56% of participants with multiple ...
Please provide your email address to receive an email when new articles are posted on . Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% ...
PHILADELPHIA -- For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ...
Participants in the OUtMATCH trial are allergic to peanuts and at least two other foods among milk, eggs, wheat, cashews, walnuts and hazelnuts. A clinical trial has found that the medication ...
ADP101 is an investigational oral immunotherapy designed to simultaneously treat allergy to multiple food allergens. The Food and Drug Administration (FDA) has granted Fast Track designation to ADP101 ...
Due to its increasing prevalence and psychological and physical effects in recent decades, food allergy (FA) has become a chronic condition in the United States (US). Recent research highlights that ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an ...
– Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College of Asthma, Allergy and Immunology (ACAAI) Meeting demonstrate dose-dependent, clinically meaningful desensitization ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results